Yeast has shown some promise as a model system to generate lead compounds that could have therapeutic potential for the cellular problems associated with neurodegenerative diseases. Along these lines, Tardiff et al.(p. 979, published online 24 October) and Chung et al. (p. 983, published online 24 October) describe the results of multiple screens in yeast that lead to the identification of a potential therapeutic compound to combat the cytotoxic affect of α-synuclein accumulation. The compound was able to reverse the pathological hallmarks of Parkinson’s disease in cultured neurons derived from patients with α-synuclein–induced Parkinson’s disease dementia.
Want To Publish your Group Article?
Click HERE to send us your group Article for publishing on our website.
- alzheimer Alzheimers Disease animal model antibiotic resistance antibiotics Bacteria Brain breast cancer cancer cell-signaling clinical trials CRISPR diabetes disease/medicine DNA drug drug research Gene Expression general health Gene therapy Genetics genetics & genomics Genomics HIV immunology immunotherapy infectious disease Malaria microbiology microbiome mutation neuroscience new therapy obesity Parkinson's disease stem cells T cells techniques therapy treatment tumor vaccine virology virus Zika virus